miR‑155, miR‑96 and miR‑99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma

Ning,Shufang; Liu,Haizhou; Gao,Bing; Wei,Wene; Yang,Aifang; Li,Jilin; Zhang,Litu

doi:10.3892/ol.2019.10606

miR‑155, miR‑96 and miR‑99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma

Authors:
- Shufang Ning
- Haizhou Liu
- Bing Gao
- Wene Wei
- Aifang Yang
- Jilin Li
- Litu Zhang
View Affiliations

Affiliations: Department of Research, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: July 11, 2019 https://doi.org/10.3892/ol.2019.10606
Pages: 3381-3387

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence has demonstrated that circulating microRNAs (miRNAs) can be utilized as potential biomarkers for the diagnosis of cancer, as well as a prognostic tool for the management of the disease. Therefore, the present study aimed to evaluate the predictive ability of miRNA (miR)‑155, miR‑96 and miR‑99a for the diagnosis and prognosis of hepatocellular carcinoma (HCC). Tissues were collected from 30 patients with HCC and their matched adjacent normal liver tissues, as well as from serum samples from 30 patients with HCC and 30 healthy controls. Reverse transcription‑quantitative PCR was used to measure the expression levels of miR‑155, miR‑96 and miR‑99a. The expression levels of miR‑155 and miR‑96 were upregulated in the tissues and serum of patients with HCC, whereas miR‑99a expression levels were decreased. Receiver operating characteristics (ROC) curve analysis revealed that circulating miR‑155, miR‑96, miR‑99a and a combination of these three miRNAs could serve as diagnostic biomarkers for HCC with areas under the curve (AUC) of 0.84, 0.824, 0.799 and 0.931, respectively. Serum α‑fetoprotein (AFP) was detected using electrochemiluminescence immunoassay analyzer. The addition of AFP with the combination of these three miRNAs offered a higher accuracy of HCC diagnosis (AUC, 0.979; sensitivity, 90.0%; specificity, 100.0%). In addition, elevated expression levels of miR‑155 and miR‑96 were associated with poor survival time of patients with HCC. The panel of miR‑155, miR‑96, miR‑99a and AFP had a higher sensitivity and specificity for the diagnosis of HCC when compared with a single marker. Furthermore, the present data suggested that miR‑155 and miR‑96 may be potential prognostic markers for the clinical management of patients with HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Margini C and Dufour JF: The story of HCC in NAFLD: From epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 36:317–324. 2016. View Article : Google Scholar : PubMed/NCBI
3	Zhang YF and Ho M: Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma. Sci Rep. 6:338782016. View Article : Google Scholar : PubMed/NCBI
4	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
5	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
6	Nagy ZB, Wichmann B, Kalmár A, Galamb O, Barták BK, Spisák S, Tulassay Z and Molnár B: Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens. Clin Epigenetics. 9:222017. View Article : Google Scholar : PubMed/NCBI
7	Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer. 137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
8	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
9	Oka S, Furukawa H, Shimada K, Hashimoto A, Komiya A, Fukui N, Tsuchiya N and Tohma S: Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease. BMC Musculoskelet Disord. 18:212017. View Article : Google Scholar : PubMed/NCBI
10	Liu X, Zhang X, Zhang Z, Chang J, Wang Z, Wu Z, Wang C, Sun Z, Ge X, Geng R, et al: Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. Int J Cancer. 141:2093–2102. 2017. View Article : Google Scholar : PubMed/NCBI
11	Gao B, Ning S, Li J, Liu H, Wei W, Wu F, Tang Y, Feng Y, Li K and Zhang L: Integrated analysis of differentially expressed mRNAs and miRNAs between hepatocellular carcinoma and their matched adjacent normal liver tissues. Oncol Rep. 34:325–333. 2015. View Article : Google Scholar : PubMed/NCBI
12	Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S and Zhang Z: Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 57:897–904. 2012. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12 body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI
15	Bašová P, Pešta M, Sochor M and Stopka T: Prediction potential of serum miR-155 and miR-24 for relapsing early breast cancer. Int J Mol Sci. 18(pii): E21162017. View Article : Google Scholar : PubMed/NCBI
16	Qu Y, Zhang H, Sun W, Han Y, Li S, Qu Y, Ying G and Ba Y: MicroRNA-155 promotes gastric cancer growth and invasion by negatively regulating transforming growth factor-β receptor 2. Cancer Sci. 109:618–628. 2018. View Article : Google Scholar : PubMed/NCBI
17	Liu F, Song D, Wu Y, Liu X, Zhu J and Tang Y: MiR-155 inhibits proliferation and invasion by directly targeting PDCD4 in non-small cell lung cancer. Thorac Cancer. 8:613–619. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhang GJ, Xiao HX, Tian HP, Liu ZL, Xia SS and Zhou T: Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med. 31:1375–1380. 2013. View Article : Google Scholar : PubMed/NCBI
19	Al-Haidari A, Algaber A, Madhi R, Syk I and Thorlacius H: MiR-155-5p controls colon cancer cell migration via post-transcriptional regulation of human antigen R (HuR). Cancer Lett. 421:145–151. 2018. View Article : Google Scholar : PubMed/NCBI
20	Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, Nan K, Yao Y and Tian T: MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 108:620–631. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhang M, Guo Y, Wu J, Chen F, Dai Z, Fan S, Li P and Song T: Roles of microRNA-99 family in human glioma. Onco Targets Ther. 9:3613–3619. 2016.PubMed/NCBI
22	Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
23	Yan B, Fu Q, Lai L, Tao X, Fei Y, Shen J, Chen Z and Wang Q: Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells. Mol Med Rep. 6:675–681. 2012.PubMed/NCBI
24	Yin H, Ma J, Chen L, Piao S, Zhang Y, Zhang S, Ma H, Li Y, Qu Y, Wang X and Xu Q: MiR-99a enhances the radiation sensitivity of non-small cell lung cancer by targeting mTOR. Cell Physiol Biochem. 46:471–481. 2018. View Article : Google Scholar : PubMed/NCBI
25	Zhang J, Jin H, Liu H, Lv S, Wang B, Wang R, Liu H, Ding M, Yang Y, Li L, et al: MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis. 3:e972014. View Article : Google Scholar : PubMed/NCBI
26	Li W, Chang J, Wang S, Liu X, Peng J, Huang D, Sun M, Chen Z, Zhang W, Guo W and Li J: miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. Oncotarget. 6:24448–24462. 2015.PubMed/NCBI
27	He K, Tong D, Zhang S, Cai D, Wang L, Yang Y, Gao L, Chang S, Guo B, Song T, et al: miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3β in oral squamous cell carcinoma Tca-8113 cells. Int J Oncol. 47:1528–1536. 2015. View Article : Google Scholar : PubMed/NCBI
28	Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y, Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep. 6:374212016. View Article : Google Scholar : PubMed/NCBI
29	Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M and Enokida H: Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol. 10:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wu H, Zhou J, Mei S, Wu D, Mu Z, Chen B, Xie Y, Ye Y and Liu J: Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J Cell Mol Med. 21:1228–1236. 2017. View Article : Google Scholar : PubMed/NCBI
31	Iwai N, Yasui K, Tomie A, Gen Y, Terasaki K, Kitaichi T, Soda T, Yamada N, Dohi O, Seko Y, et al: Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. Int J Oncol. 53:237–245. 2018.PubMed/NCBI
32	Chen Y, Dong X, Yu D and Wang X: Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Int J Clin Exp Med. 8:18462–18468. 2015.PubMed/NCBI
33	Leung WK, He M, Chan AW, Law PT and Wong N: Wnt/β-catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Lett. 362:97–105. 2015. View Article : Google Scholar : PubMed/NCBI